
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is well-positioned to succeed given the promising data from their current Phase 2 SimpliciT1 trial and the upcoming completion of enrollment in their Phase 3 CATT1 trial. Additionally, the company has a diverse pipeline of other candidates in development, providing upside potential. With a strong cash position and potential for additional financing, vTv Therapeutics is poised for success in a competitive market.
Bears say
vTv Therapeutics is facing challenges in gaining widespread adoption of its lead candidate, cadisegliatin, with only slight increases in projected penetration rates for hypoglycemia-burdened T1D patients. Despite enthusiasm from pediatric clinicians, the unpredictable needs and persistent challenges faced by adolescent T1D patients may limit the drug's potential impact. Furthermore, with a projected peak sales of only $840 million, the company's financial outlook may also be impacted by limited market penetration.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares